Remus PharmaceuticalsNSE:REMUS -3.80%55 FCF Yield % is 0.40 as of Jun. 30, 2026, which is 9% below its 10-year median of 0.44. GuruFocus rates NSE:REMUS with a GF Score™ of 55/100 and a GF Value™ of ₹2,071.36 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 117 Medical Distribution companies, Remus Pharmaceuticals ranks worse than 60.68% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Remus Pharmaceuticals FCF Yield % Related Terms
Remus Pharmaceuticals FCF Yield % Historical Data
* Premium members only.
The historical data trend for Remus Pharmaceuticals's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:REMUS vs MCK, CAH, COR: FCF Yield % Comparison
For the Medical Distribution subindustry, Remus Pharmaceuticals's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Remus Pharmaceuticals FCF Yield % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Remus Pharmaceuticals's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Remus Pharmaceuticals's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Remus Pharmaceuticals (NSE:REMUS) has a FCF Yield % of 0.40 as of Jun. 30, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Remus Pharmaceuticals and its competitors. This is near median its historical median of 0.44. According to the industry distribution chart, Remus Pharmaceuticals ranks #71 out of 117 companies in the Medical Distribution industry, placing it in the top 60.7%.
Is Remus Pharmaceuticals' FCF Yield % too high?
Remus Pharmaceuticals' current FCF Yield % of 0.40 is near median its 10-year median of 0.44. The Medical Distribution industry median FCF Yield % is 2.61. Remus Pharmaceuticals' value of 0.40 is 84.7% below this industry median. Based on the distribution chart, Remus Pharmaceuticals ranks #71 out of 117 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, Remus Pharmaceuticals has a GF Score™ of 55/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Remus Pharmaceuticals' FCF Yield % compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Remus Pharmaceuticals ranks #71 out of 117 companies for FCF Yield %. This places Remus Pharmaceuticals in the lower half of its industry. The industry median FCF Yield % is 2.61. Remus Pharmaceuticals' value of 0.40 is 84.7% below this benchmark. While the company's 10-year median is 0.44 vs. the industry median of 2.61, Remus Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Medical Distribution company?
The median FCF Yield % among Medical Distribution companies is 2.61, based on 117 companies in the industry. Companies in the top quartile (top 25%) have a FCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Remus Pharmaceuticals's current FCF Yield % of 0.40 is 84.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Remus Pharmaceuticals and its competitors. For the Medical Distribution industry, the median FCF Yield % is 2.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Remus Pharmaceuticals's current FCF Yield % is 0.40, which is near median its own 10-year median of 0.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Remus Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Remus Pharmaceuticals (NSE:REMUS) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹2,071.36, compared to a current price of ₹763.55 — trading 63.1% below its estimated fair value. The current FCF Yield % is 0.40, which is near median its 10-year median of 0.44 and 84.7% below the Medical Distribution industry median of 2.61. Remus Pharmaceuticals' overall GF Score™ is 55/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Remus Pharmaceuticals (NSE:REMUS), the current FCF Yield % is 0.40 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Remus Pharmaceuticals (NSE:REMUS) Overvalued in 2026?
Based on GuruFocus' analysis, Remus Pharmaceuticals stock appears to be undervalued.
The current stock price of ₹763.55 is trading 63.1% below its estimated GF Value™ of ₹2,071.36.
GuruFocus considers Remus Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for NSE:REMUS:
FCF Yield %: 0.40 (near median its 10-year median of 0.44)
GF Value™: ₹2,071.36 vs. price of ₹763.55 (63.1% below fair value)
Industry Position: 84.7% below the Medical Distribution median (#71 of 117)
No single metric tells the full story. See the NSE:REMUS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Remus Pharmaceuticals Ltd is engaged in the marketing & distribution of finished formulations of pharmaceutical drugs. The company also deals in API (Active Pharmaceutical Ingredient). It also provides technical consultancy services to various distributors for the preparation of reports on the dossiers of the products to be registered by them in various countries. Remus Pharmaceuticals market niche medicinal combinations. It exports generic drugs by conducting intensive market research in the pharmaceutical industry to expand its product portfolio.
55GF Score
Get the complete analysis for NSE:REMUS
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:REMUS has been successfully added to your 
